scispace - formally typeset
F

Fredrik Eriksson

Researcher at Uppsala University

Publications -  16
Citations -  566

Fredrik Eriksson is an academic researcher from Uppsala University. The author has contributed to research in topics: Tumor microenvironment & Immunotherapy. The author has an hindex of 8, co-authored 15 publications receiving 437 citations.

Papers
More filters
Journal ArticleDOI

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.

TL;DR: Lower levels of pathogenic α-synuclein demonstrated, and a reduction of motor dysfunction in transgenic mice upon peripheral administration of mAb47 was indicated, suggest immunotherapy with antibodies targeting toxic α- synuclein species holds promise as a future disease-modifying treatment in Parkinson's disease and related disorders.
Journal ArticleDOI

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

TL;DR: This study confirms previous findings that local administration of low-dose anti- CTLA4 antibody generates sustained antitumor effects and provides rationale to devise ultrasound-guided intratumoral anti-CTLA4 antibodies injection regimens to treat patients with pancreatic adenocarcinoma and other types of solid tumors.
Journal ArticleDOI

DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.

TL;DR: Safety, clinical efficacy and immunogenicity of a DNA vaccine coding for rhesus prostate specific antigen (PSA) delivered by intradermal injection and skin electroporation and T-cell reactivity observed in patients with biochemical relapse of prostate cancer without macroscopic disease are tested.
Journal ArticleDOI

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

TL;DR: This article characterized the binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance.